ERCC2 and sarcoma: Our findings of ERCC2 mutations in 3% of epithelioid sarcoma and 6.45% of perivascular epithelioid cell tumors, the trend for increased HRD scores among ERCC2-mutated sarcomas, and the trend for shorter overall survival among patients with ERCC2 mutation support the further investigation of the role of ERCC2 in sarcoma pathogenesis and treatment.